Biotest AG (HAM:BIO) Research & Development: €56.9 Mil (TTM As of Mar. 2025)


HAM:BIO Biotest AG HAM:BIO
56 GF Score
Price €40.00
View Full Analysis

What is Biotest AG Research & Development?

Biotest AG HAM:BIO +2.04% 56 Research & Development is €56.9 Mil as of Mar. 2025. GuruFocus rates HAM:BIO with a GF Score™ of 56/100.

Research & Development is the aggregate amount of research and development expenses during the year. Biotest AG's Research & Development for the three months ended in Mar. 2025 was €15.1 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was €56.9 Mil.

Biotest AG  (HAM:BIO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Biotest AG Research & Development Related Terms

Biotest AG Research & Development Historical Data

* Premium members only.

The historical data trend for Biotest AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest AG Research & Development Chart

Biotest AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.80 52.30 50.50 66.80 56.80

Biotest AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.00 14.20 17.00 10.60 15.10
HAM:BIO
56GF Score
Biotest AG HAM:BIO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biotest AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €56.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €56.9 Mil mean?
Biotest AG (HAM:BIO) has a Research & Development of €56.9 Mil as of Mar. 2025. Research and development expense is the total cost for research and development activities. View historical data on Biotest AG and its competitors.
Is Biotest AG's Research & Development too high?
Biotest AG's current Research & Development is €56.9 Mil. Overall, Biotest AG has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Biotest AG's Research & Development compare to VRTX and REGN?
Biotest AG's Research & Development of €56.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Biotest AG and its competitors. Biotest AG's current Research & Development is €56.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest AG stock overvalued right now?
Biotest AG (HAM:BIO) has a current Research & Development of €56.9 Mil. The current Research & Development is €56.9 Mil. Biotest AG's overall GF Score™ is 56/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Biotest AG (HAM:BIO), the current Research & Development is €56.9 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotest AG Business Description

Address Landsteinerstrasse 5, PO Box 10 20 40, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The company covers preclinical and clinical development of the preparations, plasma collection, production, as well as marketing and sales.
56GF Score

Get the complete analysis for HAM:BIO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€40.00
Price